PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
Associations Between Menopausal Hormone Therapy and Colorectal, Lung or Melanoma Cancer Recurrence and Mortality: A Systematic Reviews and Meta-Analysis
Fiol, G.; Lete, I.; Nieto, L.; Santaballa, A.; Pla, M.J.; Baquedano, L.; Calaf, J.; Coronado, P.; de la Viuda, E.; Llaneza, P.; Otero, B.; Sánchez-Méndez, S.; Ramírez, I.; Mendoza, N. Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review. J. Clin. Med.2023, 12, 5263.
Fiol, G.; Lete, I.; Nieto, L.; Santaballa, A.; Pla, M.J.; Baquedano, L.; Calaf, J.; Coronado, P.; de la Viuda, E.; Llaneza, P.; Otero, B.; Sánchez-Méndez, S.; Ramírez, I.; Mendoza, N. Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review. J. Clin. Med. 2023, 12, 5263.
Fiol, G.; Lete, I.; Nieto, L.; Santaballa, A.; Pla, M.J.; Baquedano, L.; Calaf, J.; Coronado, P.; de la Viuda, E.; Llaneza, P.; Otero, B.; Sánchez-Méndez, S.; Ramírez, I.; Mendoza, N. Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review. J. Clin. Med.2023, 12, 5263.
Fiol, G.; Lete, I.; Nieto, L.; Santaballa, A.; Pla, M.J.; Baquedano, L.; Calaf, J.; Coronado, P.; de la Viuda, E.; Llaneza, P.; Otero, B.; Sánchez-Méndez, S.; Ramírez, I.; Mendoza, N. Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review. J. Clin. Med. 2023, 12, 5263.
Abstract
Objective: to create a set of eligibility criteria for the use of MHT in non-gynecological cancer patients.
Methods: We searched all articles published in peer-reviewed journals up to March 2021. The PICOS standards were used and the selection criteria as follows: menopausal women of any age with non-gynecological and non-breast cancer receiving HMT, any MHT preparation (oestrogens alone or combined with a progestogen, tibolone or tissue selective oestrogen complex) or any route of administration (oral, transdermal, vaginal or intra-nasal), recurrence and mortality, randomized controlled trials, and related extension studies or follow-up reports.
Results: Women colorectal cancer survivors who use MHT have a lower risk of death from any cause than those survivors who do not use MHT. Women Skin Melanoma Survivors Using MHT Have Longer Survival than Non-MHT Survivors. There is no evidence that women lung cancer survivors who use MHT have a different survival rates than those survivors who do not use MHT.
Conclusion: MHT is safe in women who have suffered from colorectal, lung or skin melanoma cancers
The study was registered at www.prospero.org (CRD42020166658)
Keywords
cancer survival; hormonal menopausal treatment
Subject
Medicine and Pharmacology, Obstetrics and Gynaecology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
